´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2023 ÅëÇÕÇмú´ëȸ(3ÀÏÂ÷) : 2023-09-24
±³À°ÀÏÀÚ : 2023-09-24
±³À°Àå¼Ò : ´ë±¸, ¿¢½ºÄÚ
±³À°ÁÖÁ¦ : KSN-IAC(Integrated Academic Conference) 2023 ÅëÇÕÇмú´ëȸ(3ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ : ksn@ksn.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 3Á¡ (ÀÏ¹Ý 1Á¡ / Çʼö 2Á¡)
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 10 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í [»çÀüµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-20,000/ÀüÀÏ50,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-10,000¿ø/ÀüÀÏ-20,000¿ø [ÇöÀåµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-30,000/ÀüÀÏ60,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-15,000¿ø/ÀüÀÏ-30,000¿ø *¸¸65¼¼ÀÌ»óȸ¿ø, Çлý-¸éÁ¦
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 24ÀÏ Room1 09:00~09:30 ±¹¹Î°Ç°¿µ¾çÁ¶»ç, °Ç°º¸Çè½É»çÆò°¡¿ø ÀڷḦ ÀÌ¿ëÇÑ ¸¸¼ºÄáÆϺ´ ³ëÀΠȯÀÚÀÇ ÀÓ»óÀû Ư¡ ¹× ÀÔ¿ø, »ç¸Á·ü ¹× »çȸ°æÁ¦Àû ºñ¿ë Á¶»ç ¹èÀºÁø(°æ»óÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room1 09:30~10:00 Ç÷¾× Åõ¼®À» ½ÃÀÛÇÑ ³ëÀÎ ¸¸¼ºÄáÆϺ´ ȯÀÚ¿¡¼ ½ÉÀå ±â´ÉÀÇ ¿µÇ⠺м® ±è´Ù¿î(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room1 10:00~10:30 ³ëÀÎ ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼ »îÀÇ Áú ÁöÇ¥ÀÇ »ç¸Á·ü °ü·Ã¼º ¿¬±¸ Á¤À¯°æ(°æºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room1 10:30~11:00 CRRT¸¦ ½ÃÇàÇÑ °í·ÉÀÇ È¯ÀÚ¿¡¼ÀÇ vancomycin ¾à¹° ³óµµ ¿¹Ãø ¾Ë°í¸®Áò ÀÌÀå¿í(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room1 11:00~11:30 Uric acid and Cardiometabolic Syndrome: Recent Evidences Emerged ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room1 11:30~12:00 Hyperuricemia-Related Outcomes in Hospitalized Patients with COVID-19 ½ÅÁ¤È£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room1 12:00~12:30 Uric Acid and Chronic Kidney Disease: Still More to Do À±¼¼Èñ(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room1 12:30~13:00 Uric Acid and Diabetic Kidney Disease ±è¼öÇö(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room2 09:00~09:30 HDF adequacy¸¦ ¾î¶»°Ô Æò°¡ÇÒ±î?: uremic toxinÀÇ Á¦°Å ÀÌÁö¿µ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room2 09:30~10:00 ¿Ö HDF¸¦ ÇØ¾ß Çϴ°¡?: ±×¿¡ ´ëÇÑ real-world evidence (RWE) ±Ç¼ø±æ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room2 10:00~10:30 Patient outcome¿¡ ´ëÇÑ real-world evidence¸¦ ¹ÏÀ»¸¸ ÇÑ°¡? ¹®ÁÖ¿µ(°æÈñÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room2 10:30~11:00 Ư¼ö »óȲ(special situations)¿¡¼ÀÇ HDF outcomes Á¤ÇýÀ±(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 09¿ù 24ÀÏ Room2 11:00~11:30 High-volume HDF¸¦ ½ÃÇàÇϱâ À§ÇÑ Àü·« ¾ÈÁ¤³²(ÇѸ²ÀÇ´ë )
±³À°½Ã°£ 09¿ù 24ÀÏ Room2 11:30~12:00 Online HDF¸¦ ½ÇÁ¦·Î ¾î¶»°Ô ó¹æÇϴ°¡? Á¶¾ÆÁø(ÇѸ²ÀÇ´ë )
±³À°½Ã°£ 09¿ù 24ÀÏ Room2 12:00~12:30 Cost-effectivenss°¡ Àִ°¡? ÀÌÀ¯Áø(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room2 12:30~13:00 ³» ȯÀÚ¿¡°Ô ¾î¶² modality¸¦ Àû¿ëÇÒ±î?: HD vs. HDx vs. HDF Á¶¿µÀÏ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 09¿ù 24ÀÏ Room3 09:00~09:30 È£¸ðÆÒµ¥¹ÍÄí½º - ¹ÙÀÌ·¯½º¿Í ¿ì¸® Á¶Å±¸(°æÈñÀÇ´ë) Çʼö
±³À°½Ã°£ 09¿ù 24ÀÏ Room3 09:30~10:00 ½ÅÀå³»°ú ÀÇ»çÀÇ Á¤½Å°Ç°¿¡ ´ëÇÑ À±¸®Àû Á¢±Ù ±èÀº¿µ(¼¿ïÀÇ´ë) Çʼö
±³À°½Ã°£ 09¿ù 24ÀÏ Room3 10:00~10:30 ½ÅÀå Àå¾ÖÀÎ °í¿ëÁ¤Ã¥ÀÇ ÀÇ·áÀ±¸®ÇÐÀû Á¢±Ù ½Éâ¿ì(Àå¾ÖÀÎ °í¿ë°ø´Ü) Çʼö
±³À°½Ã°£ 09¿ù 24ÀÏ Room3 10:30~11:00 ½ÅÀå³»°ú À±¸®¼º Æò°¡ÀÇ ½ÇÁ¦ ÀÌÀç¿ø(G»ù º´¿ø) Çʼö